InMode Ltd. is an Israel-based company operating in the healthcare sector, within the medical-device industry focused on minimally invasive aesthetic technologies. The company develops energy-based platforms primarily using radiofrequency technology.

Its main areas of activity include:

• Body contouring and fat-reduction technologies.
• Facial rejuvenation and skin remodeling treatments.
• Radiofrequency-assisted medical procedures.
• Devices for dermatology, plastic surgery and aesthetic medicine.

Its portfolio includes platforms such as BodyTite, FaceTite, Morpheus8, AccuTite, EmbraceRF, Votiva and Optimas, designed for a range of clinical and aesthetic applications.

The company operates globally, with distribution across North America, Europe, Asia-Pacific, the Middle East and Latin America. Its structure includes R&D centers, engineering teams, clinical-validation units, regulatory divisions and global sales and training networks.

Industry dynamics affecting InMode include demand for minimally invasive procedures, technological advances in energy-based devices, regulatory requirements, competition with alternative technologies and broader trends in cosmetic medicine.

Shares of InMode Ltd. trade on the Nasdaq under the ticker INMD.

History and Development

InMode was founded in 2008 in Israel, focusing on the development of radiofrequency-based technologies for minimally invasive medical procedures.

In its early years, the company concentrated on refining radiofrequency-assisted lipolysis (RFAL), enabling controlled fat reduction combined with tissue contraction.

Throughout the 2010s, InMode expanded its product portfolio to include solutions for facial rejuvenation, body sculpting and dermatological treatments, supporting its international growth.

The company strengthened its distribution network and invested in clinical validation to support adoption among physicians and aesthetic practitioners.

In 2019, InMode completed its initial public offering (IPO) on the Nasdaq, expanding its capital base and accelerating research, development and commercialization efforts.

In recent years, the company has operated in a context of rising demand for minimally invasive procedures, expanding its product offerings and enhancing training programs for clinicians.

Additional Information

InMode Ltd. (United States) is listed on the Nasdaq and has a market capitalization of $889.66 million, with shareholders equity totaling $629.13 million.

The company employs approximately 311 people and operates in the Health sector, within the Medical Supplies and Equipment industry.

Over the past 12 months, InMode Ltd. reported $374.63 million in revenue, generating net income of $77.50 million.

Key financial metrics include a P/E ratio of 11.48, a price-to-book (P/B) ratio of 1.41, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker INMD.